Europe Renal Denervation Devices Market Size (2024 - 2029)

The European renal denervation devices market is anticipated to experience growth over the forecast period, driven by an increasing demand for procedures due to the rising prevalence of hypertension and technological advancements. Although the market faced initial setbacks during the COVID-19 pandemic, which temporarily disrupted elective procedures, it is expected to recover as healthcare services return to pre-pandemic levels. The efficacy and long-term benefits of renal denervation in managing hypertension are likely to further boost market size. However, challenges such as the painful nature of the procedure and stringent approval and reimbursement processes may hinder market expansion.

Market Size of Europe Renal Denervation Devices Industry

Europe Renal Denervation Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 37.36 %
Market Concentration Medium

Major Players

Europe Renal Denervation Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Europe Renal Denervation Devices Market Analysis

The European renal denervation devices market was valued at USD 56.92 million in the base year and is expected to register a CAGR of 37.36% over the forecast period.

The pandemic impacted the European renal denervation devices market initially. With the outbreak of COVID-19, the European renal denervation devices market experienced a moderate decline in growth. It was primarily due to the temporary cancellation of treatment and elective procedures of the non-COVID medical condition, such as cardiology and vascular procedures, which includes renal denervation procedures. The pandemic shifted most of the focus of healthcare and research on COVID-19-related diagnosis and treatment, adversely impacting the region's cardiology and vascular specialties. For instance, a study published in the European Heart Journal - Quality of Care and Clinical Outcomes by researchers of Keele University, United Kingdom, in May 2021 highlighted the significant decrease in cardiac procedures in the United Kingdom. The study stated that 45,000 procedures were postponed amid the pandemic. However, in the post-pandemic period, the number of COVID-19-positive patients decreased. Also, the lifting of the lockdown and gradual resumption of the elective procedure of the cardiology, vascular, and other non-COVID medical areas are expected to restore the normal growth rate of the market. For instance, a study published in the European Journal of Vascular and Endovascular Surgery in October 2022 highlighted the recovery and resumption of vascular procedures after the pandemic in the region. The study mentioned that most of the services have rebounded to the pre-pandemic level with the introduction of protocols for the management of the peri-operative COVID-19 risk. Thus, the COVID-19 outbreak adversely impacted the market's growth in its preliminary phase. Moreover, the market is expected to grow at a stable pace with the increasing number of procedures for renal denervation in Europe.

Furthermore, the market is expected to grow, owing to the factors, such as technological advancements, the rising prevalence of hypertension, and the long-lasting effects of the renal denervation procedure.

The prevalence of hypertension is on the rise in the European Region, which is expected to create more demand for renal denervation procedures and devices for the management of the fatality of the disease. For instance, as per the data published by the British Heart Foundation in April 2023, more than 10 million individuals in the United Kingdom have been diagnosed with high blood pressure in 2022. The adversity of the high burden of hypertension is also found in the young population as well in the regions. The renal denervation procedure has been demonstrated to be highly efficient for the long-term management of hypertension. Thus, with such benefits, efficacy, and safety of renal denervation procedures for managing hypertension, the demand for renal denervation devices is likely to increase as more procedures are performed in Europe.

Additionally, another study published in the Clinical Research in Cardiology by the researchers of Erasmus University Medical Center, the Netherlands, in July 2022 underlined the high significance of renal denervation procedure in decreasing the blood pressure of hypertension patients in a few months and putting them off of the antihypertensive drugs. The study demonstrated that the renal denervation procedure maintained the blood pressure for five years in the operated hypertension patients. The procedure also decreased the ambulatory daytime without antihypertensive drug therapy over the period. Further, a study published in the Journal of Medicine by researchers at Vilnius University, Lithuania, highlighted the long-term antihypertensive effects of renal denervation. Thus, with the increasing cases of hypertension and the long-term benefits of renal denervation, the market for renal denervation devices is expected to grow further during the forecast period in Europe.

However, the painful procedure and stringent approval process for renal denervation devices and reimbursement systems will likely impede market growth.

Europe Renal Denervation Devices Industry Segmentation

As per the scope of this report, renal denervation devices are catheters that burn the nerve in the renal arteries using by ablating it. It is a minimally invasive procedure that involves the removal of nerves from the renal artery that leads to the kidneys. It helps in regulating vasoconstriction, which optimizes the blood flow into the kidney. The European renal denervation devices market is segmented into by Technology (Radiofrequency-based, Ultrasound-based, and Micro-infusion-based) and Geography (Germany, United Kingdom, France, Italy, Spain, Rest of Europe). The report offers the value in USD million for the above segments.

By Technology
Radiofrequency-based
Ultrasound-based
Micro-infusion-based
By Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Renal Denervation Devices Market Size Summary

The European renal denervation devices market is poised for significant growth, driven by technological advancements and the increasing prevalence of hypertension. The market experienced a temporary setback due to the COVID-19 pandemic, which led to the postponement of non-COVID medical procedures, including renal denervation. However, as healthcare services resumed and protocols were established to manage COVID-19 risks, the market began to recover. The efficacy and long-term benefits of renal denervation procedures in managing hypertension have been well-documented, contributing to a rising demand for these devices across Europe. The market is expected to expand further as more procedures are performed, supported by the growing recognition of renal denervation's role in long-term hypertension management.

Ultrasound-based renal denervation devices are anticipated to witness substantial growth, attributed to their effectiveness in managing hypertension, particularly in patients resistant to conventional antihypertensive medications. The high prevalence of hypertension, exacerbated by factors such as stress, particularly among the young population, is expected to drive demand for these devices. Germany is projected to dominate the market due to its advanced medical infrastructure and significant burden of hypertension-related cardiac issues. Key players like Medtronic, Abbott, and ReCor Medical Inc. are actively contributing to market developments, further bolstering the growth prospects of the renal denervation devices market in Europe.

Explore More

Europe Renal Denervation Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Hypertension

      2. 1.2.2 Long Lasting Effect of the Procedure

    3. 1.3 Market Restraints

      1. 1.3.1 Painful Procedure

      2. 1.3.2 Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems

    4. 1.4 Industry Attractiveness - Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Technology

      1. 2.1.1 Radiofrequency-based

      2. 2.1.2 Ultrasound-based

      3. 2.1.3 Micro-infusion-based

    2. 2.2 By Geography

      1. 2.2.1 Germany

      2. 2.2.2 United Kingdom

      3. 2.2.3 France

      4. 2.2.4 Italy

      5. 2.2.5 Spain

      6. 2.2.6 Rest of Europe

Europe Renal Denervation Devices Market Size FAQs

The Europe Renal Denervation Devices Market is projected to register a CAGR of 37.36% during the forecast period (2024-2029)

Medtronic, Abbott (St. Jude Medical Inc.), ReCor Medical Inc., Mercator MedSystems and Terumo Corporation are the major companies operating in the Europe Renal Denervation Devices Market.

Europe Renal Denervation Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)